Downgrading Icon's Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback

Icon is one of a handful of global contract research organizations with the infrastructure to carry out large, late-stage clinical trials. While Icon operates on a significant global scale with extensive regulatory knowledge, we no longer view its advantages as durable enough to maintain adjusted returns on invested capital exceeding its cost of capital over the next decade.